$21.11
chg
-0.56 (-2.58%)
quotes and stock data may be delayed 15 minutes
My Notes
Only BPIQ Pro members can create company notes. Learn more here.
52 wk low
10.52
52 wk hi
30.79
Cash
$161.1M
Burn Rate (Qtr)
$5.7M
Mkt Cap
$515.3m
Avg Volume
65,268
*cash/burn updated:
Q1 '22
Drug Pipeline
Click the button to see the updated pipeline
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
Catalyst Date
Loading Catalysts...
search in progress
Pipeline powered by
AVTE
Company Profile
Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Recent Posts
See what the community is saying - click to see full post.